A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial

BJU International, 05/14/2012

The authors found a 55% incidence of severe pain after ureteric stent removal. A single dose of a non–steroidal anti–inflammatory drug before stent removal prevents severe pain after ureteric stent removal.

Methods

  • A prospective, randomised, double-blind, placebo-controlled trial was performed at the authors institution.
  • Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal.
  • Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal
  • Pain medication use after ureteric stent removal was measured using morphine equivalents.

Results

  • In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group.
  • The most common indication for ureteroscopy was urolithiasis (14 patients).
  • The proportion of patients with severe pain (VAS score of ≥ 7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01).
  • There were no complications related to the use of rofecoxib.

Print Article Summary Cat 2 CME Report